RESEARCH TRIANGLE PARK, N.C. - BioCryst (NASDAQ:BCRX) Pharmaceuticals, Inc. (NASDAQ:BCRX) has announced its plan to present four abstracts on ORLADEYO® (berotralstat), an oral treatment for hereditary angioedema (HAE), at the upcoming Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI). The conference is scheduled to take place in Boston from October 24-28, 2024.
The presentations will focus on the adherence and persistence of patients to the treatment, sustained reductions in HAE attack rates, and patient preferences for ORLADEYO as a long-term prophylactic treatment. The data will be showcased through ePosters accessible to registered attendees both online and in person at the event.
ORLADEYO® (berotralstat) is recognized as the first and only oral, once-daily medication specifically designed to prevent HAE attacks in adults and pediatric patients aged 12 and older. The drug functions by reducing the activity of plasma kallikrein, a component that contributes to the swelling characteristic of HAE.
The safety and effectiveness of ORLADEYO for acute HAE attacks have not been established, and its use is not recommended for such purposes. The medication carries a recommended dosage of 150 mg once daily, with a reduced dosage advised for patients with moderate or severe hepatic impairment. It is also noted that berotralstat can interact with other drugs, necessitating monitoring and dose adjustments when used in conjunction with certain medications.
BioCryst emphasizes that the effectiveness of ORLADEYO in pediatric patients under 12 years of age has not been established. Similarly, there is limited data on the drug's effects during pregnancy and on breastfed infants.
The company, known for its commitment to developing treatments for rare diseases, has commercialized ORLADEYO and continues to advance its pipeline of therapeutic candidates.
This news is based on a press release statement from BioCryst Pharmaceuticals , Inc. The company's forward-looking statements about the performance and potential of ORLADEYO are subject to various risks and uncertainties that could cause actual results to differ materially from expectations.
In other recent news, BioCryst Pharmaceuticals has been making significant strides. The company has initiated a Phase 1 clinical trial for its investigational drug BCX17725, aimed at treating Netherton syndrome. In addition, BioCryst secured a $69 million contract from the U.S. Department of Health and Human Services for its influenza treatment, RAPIVAB. The company also reported strong demand for its hereditary angioedema treatment, ORLADEYO, leading to an upgraded revenue forecast for the year, now expected to fall between $420 million and $435 million. In a recent development, BioCryst finalized a deal with the pan-Canadian Pharmaceutical Alliance to incorporate ORLADEYO into public formularies, expanding patient access across Canada. Dr. Donald S. Fong was also appointed as the new chief medical officer. However, the BCX10013 program was discontinued due to insufficient drug activity. These are some of the recent developments at BioCryst Pharmaceuticals.
InvestingPro Insights
BioCryst Pharmaceuticals' upcoming presentations at the ACAAI Annual Scientific Meeting align with the company's recent financial performance and market position. According to InvestingPro data, BioCryst has shown impressive revenue growth, with a 24.65% increase over the last twelve months as of Q2 2024, and an even more robust 32.54% quarterly revenue growth in Q2 2024. This growth trajectory suggests that ORLADEYO, as the company's flagship product, is gaining traction in the market.
The company's market capitalization stands at $1.5 billion, reflecting investor confidence in BioCryst's potential. However, it's worth noting that the company is currently operating at a loss, with an adjusted operating income of -$55.39 million over the last twelve months. This is not uncommon for biopharmaceutical companies investing heavily in research and development.
An InvestingPro Tip indicates that BioCryst's revenue growth has been accelerating, which aligns with the company's focus on presenting data that could further support ORLADEYO's market position. Another InvestingPro Tip suggests that analysts have recently revised their earnings expectations upwards for the company, potentially influenced by the promising outlook for ORLADEYO.
For investors interested in a deeper analysis, InvestingPro offers 11 additional tips for BioCryst Pharmaceuticals, providing a more comprehensive view of the company's financial health and market prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.